Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Stock Information | RedChip

Processa Pharmaceuticals Inc. (NASDAQ: PCSA)


$1.78
+0.0400 ( +2.30% ) 20.7K

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Market Data


Open


$1.78

Previous close


$1.74

Volume


20.7K

Market cap


$5.00M

Day range


$1.71 - $1.77

52 week range


$1.40 - $18.00

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 14 Jul 02, 2024
8-k 8K-related 13 May 21, 2024
10-q Quarterly Reports 51 May 10, 2024
def Proxies and info statements 2 Apr 29, 2024
4 Insider transactions 1 Apr 12, 2024
4 Insider transactions 1 Apr 12, 2024
4 Insider transactions 1 Apr 12, 2024
4 Insider transactions 1 Apr 12, 2024
4 Insider transactions 1 Apr 12, 2024
8-k 8K-related 17 Apr 11, 2024

Latest News